Why BioAge Labs, Inc.’s (BIOA) Stock Is Down 61.95%
As of Friday, July 31, BioAge Labs, Inc.’s BIOA share price has dipped by 61.95%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Commentary & Analysis
Why BioAge Labs, Inc.’s (BIOA) Stock Is Down 64.79%
As of Friday, July 31, BioAge Labs, Inc.’s BIOA share price has dipped by 64.79%, which has investors questioning if this is right time to buy.Omar Beirat
Why BioAge Labs, Inc.’s (BIOA) Stock Is Down 5.70%
As of Wednesday, July 29, BioAge Labs, Inc.’s BIOA share price has dipped by 5.70%, which has investors questioning if this is right time to buy.Michael Rose
Why BioAge Labs, Inc.’s (BIOA) Stock Is Up 5.28%
As of Friday, July 17, BioAge Labs, Inc.’s BIOA share price has surged by 5.28%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why BioAge Labs, Inc.’s (BIOA) Stock Is Down 7.48%
As of Monday, July 13, BioAge Labs, Inc.’s BIOA share price has dipped by 7.48%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | BIOA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,104.7 | $569.9 | 46% |
|
| Shares Out (Mil) | 42.5 | 44.8 | 44% |
|
| Institutional Ownership | 96.3% | 84.6% | 70% |
|
| Float (Mil) | 35.0 | 45.1 | 39% |
|
| Beta | na | 0.67 | na |
|
| Avg Daily Volume (000s) | 624 | 294 | 63% |
|
| Price Change (52-week) |
454.9% | 65.2% | 99% |
|
| Growth | BIOA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | na | (2.0%) | na |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 7 | 7 | |
| Current EPS | ($0.625) | ($2.478) | ($2.040) | |
| Month Ago EPS | ($0.632) | ($2.492) | ($2.060) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | ($0.640) | ($2.600) | ($2.776) | |
| Year/Year Chg | 19.3% | 10.5% | 28.0% | |
| Financials | BIOA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $10 | $230 | 9% |
|
| Net Income (TTM) (Mil) | ($90) | ($11) | 11% |
|
| EPS (TTM) | ($2.392) | ($0.600) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($88) | ($6) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($16) | $4 | 28% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $7 | 20% |
|
| Enterprise Value (Q1) (Mil) | $426 | $493 | 33% |
|
| Valuation | BIOA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.91 | 2.89 | 64% |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | BIOA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (707.2%) | 65.9% | 0% |
|
| Net Margin | (871.8%) | (0.2%) | 0% |
|
| ROA | (24.3%) | (25.5%) | 19% |
|
| ROE | (26.0%) | (21.4%) | 21% |
|
| Liabilities to Assets | 4.7% | 35.5% | 2% |
|
| F-Score | 4 | 3 | 34% |
|
BioAge Labs, Inc. did not pass any screens on 7/30/2026.
